Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COEP NYSE:IBIO NASDAQ:KALA NASDAQ:MNOV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOEPCoeptis Therapeutics$13.32+5.2%$10.68$2.31▼$14.70$61.03M-0.5945,924 shs41,602 shsIBIOiBio$0.82-0.9%$0.73$0.56▼$6.89$16.07M0.61.54 million shs563,945 shsKALAKALA BIO$11.22+5.9%$6.89$2.92▼$11.68$74.35M-1.81122,558 shs404,474 shsMNOVMediciNova$1.31-2.2%$1.31$1.13▼$2.55$65.72M0.3563,949 shs72,019 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOEPCoeptis Therapeutics+5.21%-1.04%+21.98%+44.31%+242.24%IBIOiBio-0.90%+3.38%+19.90%+6.54%-57.41%KALAKALA BIO+5.95%+21.82%+57.14%+205.72%+90.17%MNOVMediciNova-2.24%-0.18%-2.96%-7.09%-4.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOEPCoeptis Therapeutics0.5704 of 5 stars0.03.00.00.02.51.70.0IBIOiBio1.8854 of 5 stars3.50.00.00.02.80.00.6KALAKALA BIO3.4805 of 5 stars2.52.00.04.43.30.80.6MNOVMediciNova2.196 of 5 stars3.83.00.00.02.10.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOEPCoeptis Therapeutics 0.00N/AN/AN/AIBIOiBio 3.00Buy$5.00511.47% UpsideKALAKALA BIO 3.00Buy$13.0015.86% UpsideMNOVMediciNova 3.50Strong Buy$7.00434.35% UpsideCurrent Analyst Ratings BreakdownLatest IBIO, COEP, KALA, and MNOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.007/24/2025MNOVMediciNovaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.007/11/2025KALAKALA BIOLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/25/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.006/16/2025MNOVMediciNovaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.006/2/2025KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$15.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOEPCoeptis TherapeuticsN/AN/AN/AN/A$1.47 per shareN/AIBIOiBio$375K42.86N/AN/A$1.41 per share0.58KALAKALA BIO$3.89M20.25N/AN/A($0.46) per share-24.39MNOVMediciNova$1MN/AN/AN/A$1.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOEPCoeptis Therapeutics-$10.88M-$5.80N/A∞N/AN/A-201.73%-108.46%N/AIBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/AKALAKALA BIO-$38.51M-$6.79N/AN/AN/AN/A-686.43%-76.81%11/11/2025 (Estimated)MNOVMediciNova-$11.04M-$0.25N/AN/AN/AN/A-23.12%-21.85%11/12/2025 (Estimated)Latest IBIO, COEP, KALA, and MNOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025COEPCoeptis TherapeuticsN/A-$1.17N/A-$1.17N/A$0.20 million8/14/2025Q2 2025MNOVMediciNova-$0.07-$0.07N/A-$0.07N/A$0.14 million8/8/2025Q2 2025KALAKALA BIO-$1.82-$1.71+$0.11-$1.71N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOEPCoeptis TherapeuticsN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AMNOVMediciNovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOEPCoeptis Therapeutics0.020.830.83IBIOiBio0.051.761.76KALAKALA BIO3.192.102.10MNOVMediciNovaN/A13.2613.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOEPCoeptis Therapeutics13.88%IBIOiBio7.90%KALAKALA BIO24.61%MNOVMediciNova9.90%Insider OwnershipCompanyInsider OwnershipCOEPCoeptis Therapeutics24.25%IBIOiBio0.58%KALAKALA BIO8.32%MNOVMediciNova13.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOEPCoeptis Therapeutics24.82 million3.65 millionNot OptionableIBIOiBio10019.66 million9.82 millionN/AKALAKALA BIO307.02 million6.44 millionNot OptionableMNOVMediciNova10N/AN/AOptionableIBIO, COEP, KALA, and MNOV HeadlinesRecent News About These CompaniesMediciNova's (MNOV) Buy Rating Reaffirmed at D. Boral CapitalAugust 29 at 8:30 AM | marketbeat.comMediciNova, Inc. Achieves Enrollment Target for COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 for ALS TreatmentAugust 26, 2025 | quiverquant.comQMediciNova Achieves Enrollment in COMBAT-ALS Clinical TrialAugust 26, 2025 | globenewswire.comMediciNova files to sell 25M shares of common stock for holdersAugust 22, 2025 | msn.comMediciNova (NASDAQ:MNOV) Posts Earnings Results, Meets ExpectationsAugust 18, 2025 | marketbeat.comMediciNova: Q2 Earnings SnapshotAugust 14, 2025 | sfgate.comMediciNova (MNOV) to Release Quarterly Earnings on ThursdayAugust 7, 2025 | marketbeat.comMediciNova signs standby equity purchase agreement for up to $30MAugust 1, 2025 | msn.comMediciNova Secures $30 Million Equity Purchase AgreementAugust 1, 2025 | tipranks.comMediciNova, Inc. Announces Standby Equity Purchase Agreement for Up to $30 Million in Common StockJuly 31, 2025 | quiverquant.comQMediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 MillionJuly 31, 2025 | globenewswire.comMediciNova, Inc.: MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical TrialsJuly 24, 2025 | finanznachrichten.deMediciNova, Inc. Reports Progress in Enrollment for Clinical Trials of MN-166 and MN-001July 24, 2025 | quiverquant.comQMediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical TrialsJuly 24, 2025 | globenewswire.comMediciNova, Inc. (MNOV) stock price, news, quote & history – Yahoo ...July 12, 2025 | au.finance.yahoo.comMediciNova, Inc. (MNOV) stock price, news, quote & history - Yahoo FinanceJune 26, 2025 | sg.finance.yahoo.comMediciNova price target lowered to $5 from $6 at B. RileyJune 17, 2025 | finance.yahoo.comMediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025April 14, 2025 | globenewswire.comMediciNova says first patient enrolled in EAP trial to evaluate MN-166April 9, 2025 | markets.businessinsider.comFirst Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) PatientsApril 8, 2025 | globenewswire.comMNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…December 9, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIBIO, COEP, KALA, and MNOV Company DescriptionsCoeptis Therapeutics NASDAQ:COEP$13.32 +0.66 (+5.21%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$13.34 +0.02 (+0.15%) As of 08/29/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.iBio NYSE:IBIO$0.82 -0.01 (-0.90%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.80 -0.02 (-2.65%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.KALA BIO NASDAQ:KALA$11.22 +0.63 (+5.95%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$11.58 +0.37 (+3.25%) As of 08/29/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.MediciNova NASDAQ:MNOV$1.31 -0.03 (-2.24%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.31 0.00 (0.00%) As of 08/29/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
